Search

Displaying results 8531 - 8540 of 8547 in total
  1. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.

  2. Drug

    DTS-201

    go.drugbank.com/drugs/DB06071
    Experimental

    solid tumors, including tumors sensitive to doxorubicin and potentially other tumors which are not currently treated with doxorubicin but which express high levels of CD-10* or TOP** peptidases, such as

  3. Drug

    Gam-COVID-Vac

    go.drugbank.com/drugs/DB15848
    Investigational

    Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia.

  4. Drug

    Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15740
    Investigational

    Currently, OM-MSCs does not have wide application as there is not yet a standard and unambiguous protocol for OM-MSC collection, isolation, and therapeutic application.

  5. Drug

    Horse chestnut

    go.drugbank.com/drugs/DB13195
    Investigational

    Horse chestnut is a flowering plant commonly referred to as *Aesculus hippocastanum*.

  6. Drug

    Ellagic acid

    go.drugbank.com/drugs/DB08846
    Investigational

    Ellagic acid is present in several fruits such as cranberries, strawberries, raspberries, and pomegranates.

  7. Drug

    Epicept NP-1

    go.drugbank.com/drugs/DB05492
    Investigational

    EpiCept NP-1 Cream is a patented formulation containing two FDA-approved drugs, amitriptyline (a widely-used antidepressant) and ketamine (an NMDA antagonist that is used as an anesthetic).

  8. Drug

    PI-0824

    go.drugbank.com/drugs/DB05516
    Investigational

    Peptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824.

  9. Drug

    MVA-BN-brachyury-TRICOM vaccine

    go.drugbank.com/drugs/DB17424
    Investigational

    [L44513] MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of the fowlpox virus(FPV)‐Brachyury booster vaccine.

  10. Drug

    OSI-7836

    go.drugbank.com/drugs/DB05837
    Experimental

    OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine.